MedTrace Logo

Effects of Psilocybin in Post-Treatment Lyme Disease

NCT05305105 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-08-20

No results posted yet for this study

Summary

This study will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).

Conditions

  • Post-Treatment Lyme Disease
  • Chronic Lyme Disease
  • Lyme Disease, Chronic

Interventions

DRUG

Psilocybin

Dosing at the first session will be 15mg. For the second session participants will either remain at the initial dose, or increase to 25mg.

Sponsors & Collaborators

  • Steven & Alexandra Cohen Foundation

    collaborator OTHER

  • Usona Institute

    collaborator OTHER

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Albert Garcia-Romeu, PhD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2024-10-26
Completion
2025-04-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305105 on ClinicalTrials.gov